SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ELDN

Eledon Pharmaceuticals, Inc. (ELDN)

NASDAQ: ELDN · USD
Healthcare · Biotechnology
$1.78-$0.12 (-6.32%)
 
Market cap
$150M
Insider Score
Analyst consensus
Website
Market Cap$150.34M+28.1%
Revenue (ttm)n/a
Net Income-$85.03M
EPS-$0.73
Shares Out84.46M
PE Ration/a
Forward PE-2.35
Dividendn/a
Ex-Dividend Daten/a
Volume1,292,761
Open$1.87
Previous Close$1.90
Day's Range$1.76 - $2.00
52-Week Range$1.39 - $4.49
Beta0.96
AnalystsStrong Buy
Price Target$9.00(+405.62%)
Earnings DateNov 13, 2026

About ELDN

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Address
19800 MacArthur Boulevard, Irvine, CA, 92612, United States
Market Cap
150 million
Employees
33
Industrial Classification
Biotechnology
1 Day
-6.32%
5 Days
-15.84%
1 Month
-22.61%
6 Months
-54.24%
1 Year
+28.06%

$ELDN stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ELDN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ELDN's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ELDN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ELDN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ELDN from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from ELDN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
100% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IWCiShares Micro-Cap ETF0.05%

Weight is the stock’s share of each fund’s holdings.